CellCeutix pharmaceutical company

from ceo

In over 25 years working for a very large pharmaceutical company you may have heard of--Pfizer--I learned a few things about the pharmaceutical business.  Perhaps the most important thing I learned is that the vast majority of the value in the business comes from very few things.  Two of the most important are high quality data and patents.  An organization that spends most of its time on critical value-creating issues, should be able to create value for shareholders without wasting a lot of time and money.
 
I also learned a few things about large organizations.  I learned that large organizations have vast resources and expertise but they tend to be slow, bureaucratic and afraid of new ideas, especially from outside.

At Cellceutix, we have an exciting pipeline.  We have the expertise of a large pharmaceutical company, but we're also focused, nimble and willing to supplement our own creative energies with ideas from the outside.  We're focused on our lead candidate, Kevetrin, which we plan to develop for head and neck cancer.  And we're focused on developing high quality data and patents to support Kevetrin.  We're also open to new ideas from outside as well as inside.  As a matter of fact, our pipeline already includes compounds licensed from the outside to supplement those invented by one of our co-founders, Dr. Krishna Menon. We're willing to partner with anyone who will help us meet our goals.  
 
When you put all this together, it means we at Cellceutix have a very exciting opportunity to create real value for our shareholders, as well as for our ultimate customers, the patients.

George W. Evans, JD, MBA
Chief Executive Officer